<!DOCTYPE html>
<html lang="" xml:lang="">
  <head>
    <title>SARS-CoV-2 Pandemic 2019-2020</title>
    <meta charset="utf-8" />
    <meta name="author" content="Authors: Elena Dudukina, Raquel Raquel Avelar, Deirdre Cronin Fenton" />
    <meta name="date" content="2020-04-07" />
    <link rel="stylesheet" href="xaringan-themer.css" type="text/css" />
  </head>
  <body>
    <textarea id="source">
class: center, middle, inverse, title-slide

# SARS-CoV-2 Pandemic 2019-2020
## Introduction to the little known
### Authors: Elena Dudukina, Raquel Raquel Avelar, Deirdre Cronin Fenton
### 2020-04-07

---






 # Epidemics are not new to human history
- **1348-1351** **Bubonic plague** (Second plague pandemic, or "Black death")
    - Bacterium _Yersinia pestis_
    - Estimated 25-75 million deaths in Europe and Asia
    - Reduced 30% to 60% of Europe's population ([Austin Alchon, 2003](https://books.google.dk/books?id=YiHHnV08ebkC&amp;pg=PA21&amp;redir_esc=y#v=onepage&amp;q&amp;f=false))
    - No treatment
    
.footnote[_"The trend of recent research is pointing to **45–50% of the European population dying during a four-year period***. There is a fair amount of geographic variation. In Mediterranean Europe, areas such as **Italy, the south of France and Spain**, where plague ran for about four years consecutively, it was probably closer to **75–80% of the population**. In **Germany and England** it was probably closer to **20%**"_ (Philip Daileader, The Late Middle Ages, 2007)]
---
- **1918-1919** 1st pandemic caused by **H1N1 influenza virus** ("Spanish flu")
    - Basic reproductive number (R0): 1.5 (1.2–3.0)([Vynnycky, 2007](https://academic.oup.com/ije/article/36/4/881/667165))
    - ~ 500 million estimated infected (33% of the world's population) ([Taubenberger, 2006](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291398/))
    - 17 to 20 million deaths globally
    - Severe disease with case-fatality rate &gt;2.5%
    - No treatment
    - No prevention (no vaccine)
--

- **2002-2004** **SARS** (SARS-CoV virus)
    - Basic reproductive number (R0): 2.0-4.0 ([WHO, 2003](https://www.who.int/csr/sars/en/WHOconsensus.pdf))
    - 8096 cases
    - ~774 deaths in 32 countries **→** case fatality rate 9.6% ([WHO, 2004](https://www.who.int/csr/sars/country/table2004_04_21/en/))
    - Vaccine inducing neutrolizing antibodies ([Chien-Te Tseng, 2012](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335060/))

--

- **2009** 2nd pandemic caused by **H1N1 influenza virus** (H1N1/09, or "Swine flue")
    - Basic reproductive number (R0): 1.5 (1.3–1.7)
    -	~ 0.7–1.4 billion estimated infected worldwide
    -	~ 151,700–575,400 estimated deaths worldwide
    -	Vaccine available
    
---

- **2012-present** **MERS** (MERS-CoV)
    - Basic reproductive number (R0) &lt;1 ([WHO, 2019](https://apps.who.int/iris/bitstream/handle/10665/326126/WHO-MERS-RA-19.1-eng.pdf?ua=1))
      - Heterogenous R0: 1.0-5.7 at the start of the outbreak → &lt; 1.0 [Bernard-Stoecklin, 2019](https://www.nature.com/articles/s41598-019-43586-9)
    - 2012-2016: 1841 laboratory confirmed cases → 80% in the Kingdom of Saudi Arabia
    -	~ 35% (n=652) died
--

-	**2014-2016 Ebola**
    -	Basic reproductive number (R0): 1.7-2.0 ([WHO Ebola Response Team, 2016](https://www.who.int/ebola/publications/nejm-after-ebola.pdf) )
    - ~ 28,542 cases
    -	~ 11,299 deaths
    -	CFR ~ 40%

---

 # Emerging Infectious Diseases
**Identification of infectious agents and diseases that were not recognized before**

**Infection states**

- Progression-Related

State of Infection | Definition| Alternative Terms
 --------|---------|---------
Colonization | Transient colonization tissue invasion | Transient colonization
Infection | Agent is present in host tissues without signs, symptoms, or laboratory evidence of tissue damage | Subclinical infection, asymptomatic infection
Latency | Infection in which the agent has invaded the host and is in a nonreplicating, noninfectious, but viable state | Latent infection, persistent infection, chronic infection
Disease | Agent is replicating in host tissues with signs, symptoms, or laboratory evidence of tissue damage | Clinical disease, symptomatic infection
Cure | Agent has been eliminated from host tissue (may persist on surface) | Resolution

---
**Infection states**

- Transmission-Related

State of Infection | Definition| Alternative Terms
 --------|---------|---------
Preinfectious | Host is infected but has not become infectious | Latency, preinfective period
Infectious | Host is capable of transmitting agent to others | Contagiousness, infective period
Postinfectious | Host is no longer capable of transmission | Cure, postinfective period

.footnote[Rothman KJ, Modern Epidemiology, 3rd Edition]

---
# Modeling infectious diseases
- Agent-based models
- Multi-level models
- Network models
- Compartmental models
    - SIR (Susceptible → Infectious → Recovered)
    - SEIR (Susceptible → Exposed → Infectious → Recovered)
    - SEIS (Susceptible → Exposed → Infectious → Susceptible)
    - Other modifications to accomodate duration of post-infection immunity, vaccination, etc.

---
# Key definitions
- Attack rate
  - The proportion of the population which contracts the disease fro the population at risk


- Case-fatality risk (CFR)
  - The probability that a person dies from an infection given that they are a case


- Infection-fatality risk (IFR)
  - Defines a case as a person who has shown evidence of infection, either by clinical detection of the pathogen or by seroconversion or other immune response

.footnote[[Lipsitch, 2015](https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003846)]

---
# Basic Reproductive Number
.pull-left[
- **R0** (often pronounced _"R naught"_)
  - The **average number of secondary cases** of an infection that occur **in a completely
susceptible population following a single infectious case**
  
  _How many other people one contagious individual will infect in non-immune population?_
  
  - Mathematical modeling of transmission within populations
  ]

.right[
![](r0-covid19.png)
]

.footnote[
[Vox, 2020](https://www.vox.com/science-and-health/2020/4/2/21197617/coronavirus-pandemic-covid-19-death-rate-transmission-risk-factors-lockdowns-social-distancing)

[NEJM, 2020](https://www.nejm.org/doi/full/10.1056/NEJMoa2001316)]

---

# Coronavirus disease (COVID-19) outbreak

- **SARS-CoV-2**
- β-coronavirus (other two known β-CoVs are SARS-CoV and MERS-CoV)
- Origin:  bats via unknown intermediate hosts to infect humans
- Uses angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV, to infect humans
- Incubation period
    - Median 5.1 days (95% CI, 4.5 to 5.8 days), and 97.5% of those who develop symptoms will do so within 11.5 days ([mainland China data](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081172))
    - China CDC: 10-14 days
    - USA CDC: [2-14 days](https://www.cdc.gov/coronavirus/2019-ncov/about/symptoms.html)
- Period of infectivity: 90% negative viral RNA tests on nasopharyngeal swabs by 10 days after the onset of symptoms ([Liu, 2020](https://www.thelancet.com/action/showPdf?pii=S1473-3099%2820%2930232-2))
- Immunity: preliminary data for neutralizing antibodies ([Kai-Wang To, 2020](https://www.thelancet.com/action/showPdf?pii=S1473-3099%2820%2930196-1); [Ju, 2020](https://www.biorxiv.org/content/10.1101/2020.03.21.990770v1.full.pdf))

.right[![:scale 30%](SARS CoV2.jfif)]

---
# Testing for COVID-19
- Different testing patterns/kits in different countries

- Probability of being tested is not independent of disease severity and of the outcome

- RT-PCR:
    - Tests are not perfect
      - Analytical Sensitivity 95%
      - Positive (COVID-19_N_P) – positive for all targets detected (Ct &lt; 40)
      - [Analytical Specificity: no cross-reactivity](https://www.fda.gov/media/136151/download)
      
- No reliable data on comparative accuracy of oropharyngeal vs nasopharyngeal swabs for diagnosis of [COVID-19](https://www.cebm.net/covid-19/comparative-accuracy-of-oropharyngeal-and-nasopharyngeal-swabs-for-diagnosis-of-covid-19/)

---
**Total number of tests for COVID-19**
&lt;iframe src="https://ourworldindata.org/grapher/full-list-total-tests-for-covid-19" style="width: 100%; height: 550px; border: 0px none;"&gt;&lt;/iframe&gt;

---
** Tests per 1 million population**
&lt;iframe src="https://ourworldindata.org/grapher/full-list-cumulative-total-tests-per-million" style="width: 100%; height: 550px; border: 0px none;"&gt;&lt;/iframe&gt;

---
**Number of registrered/confirmed COVID-19 cases**

&lt;iframe src="https://ourworldindata.org/grapher/covid-confirmed-cases-since-100th-case" style="width: 100%; height: 550px; border: 0px none;"&gt;&lt;/iframe&gt;

---
**Number of registered/confirmed COVID-19 cases and case-fatality rates**

&lt;iframe src="https://ourworldindata.org/grapher/covid-19-total-confirmed-cases-vs-total-confirmed-deaths?time=0..76" style="width: 100%; height: 550px; border: 0px none;"&gt;&lt;/iframe&gt;

---
**Case-fatality rates among registrered/confirmed COVID-19 cases**

&lt;iframe src="https://ourworldindata.org/grapher/coronavirus-cfr?year=17&amp;time=-2..76" style="width: 100%; height: 550px; border: 0px none;"&gt;&lt;/iframe&gt;
 
---
![:scale 75%](COVID-CFR-by-age.png)
---
**Beware of bias when calculating case-fatality rate**
- The data we use to estimate the CFR are often gathered for other purposes

- Challenging &amp; constantly changing circumstances

- Preferential testing and counting of severe cases → overestimation

- At any point during ongoing epidemic we haven't yet observed disease outcomes for everyone → underestimation

- Delayed reporting: outcomes observed now are reported later

- Forward contact tracing → pre-symptomatic individuals → less prone to bias CFR estimates

- Comparison of CFR across groups
  - E.g., hospitalized vs non-hospitalized → multiple competing biases
      - Suvivorship
      - Selection
      - Confounding

.footnote[[Lipsitch, 2015](https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003846)]

---
# Treatment of COVID19
- Only symptomatic treatment
- Clinical trials for variety of agents (antiviral and other)
- Possibility of low-quality publications
---
# Chloroquine + azytromycin study
---
# Antibody response and vaccine development

---
# What next?

---
# Thank you for attention

---
# Resources
- https://ourworldindata.org/coronavirus#
- http://www.healthdata.org/covid/faqs
- http://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-13-europe-npi-impact/
- https://twitter.com/mlipsitch
- https://twitter.com/CT_Bergstrom
- https://twitter.com/EpiEllie
    </textarea>
<style data-target="print-only">@media screen {.remark-slide-container{display:block;}.remark-slide-scaler{box-shadow:none;}}</style>
<script src="https://remarkjs.com/downloads/remark-latest.min.js"></script>
<script src="macros.js"></script>
<script>var slideshow = remark.create({
"ratio": "16:9",
"highlightStyle": "github",
"highlightLines": true,
"countIncrementalSlides": false,
"background-image": "url(aulogo_uk_var2_white.png)",
"background-position": "top right",
"background-size": "110px 120px",
"layout": true
});
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function(d) {
  var s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})(document);

(function(d) {
  var el = d.getElementsByClassName("remark-slides-area");
  if (!el) return;
  var slide, slides = slideshow.getSlides(), els = el[0].children;
  for (var i = 1; i < slides.length; i++) {
    slide = slides[i];
    if (slide.properties.continued === "true" || slide.properties.count === "false") {
      els[i - 1].className += ' has-continuation';
    }
  }
  var s = d.createElement("style");
  s.type = "text/css"; s.innerHTML = "@media print { .has-continuation { display: none; } }";
  d.head.appendChild(s);
})(document);
// delete the temporary CSS (for displaying all slides initially) when the user
// starts to view slides
(function() {
  var deleted = false;
  slideshow.on('beforeShowSlide', function(slide) {
    if (deleted) return;
    var sheets = document.styleSheets, node;
    for (var i = 0; i < sheets.length; i++) {
      node = sheets[i].ownerNode;
      if (node.dataset["target"] !== "print-only") continue;
      node.parentNode.removeChild(node);
    }
    deleted = true;
  });
})();
(function() {
  "use strict"
  /* Replace <script> tags in slides area to make them executable
   *
   * Runs after post-processing of markdown source into slides and replaces only
   * <script>s on the last slide of continued slides using the .has-continuation
   * class added by xaringan. Finally, any <script>s in the slides area that
   * aren't executed are commented out.
   */
  var scripts = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container:not(.has-continuation) script'
  );
  if (!scripts.length) return;
  for (var i = 0; i < scripts.length; i++) {
    var s = document.createElement('script');
    var code = document.createTextNode(scripts[i].textContent);
    s.appendChild(code);
    scripts[i].parentElement.replaceChild(s, scripts[i]);
  }
  var scriptsNotExecuted = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container.has-continuation script'
  );
  if (!scriptsNotExecuted.length) return;
  for (var i = 0; i < scriptsNotExecuted.length; i++) {
    var comment = document.createComment(scriptsNotExecuted[i].outerHTML)
    scriptsNotExecuted[i].parentElement.replaceChild(comment, scriptsNotExecuted[i])
  }
})();
(function() {
  var links = document.getElementsByTagName('a');
  for (var i = 0; i < links.length; i++) {
    if (/^(https?:)?\/\//.test(links[i].getAttribute('href'))) {
      links[i].target = '_blank';
    }
  }
})();
// adds .remark-code-has-line-highlighted class to <pre> parent elements
// of code chunks containing highlighted lines with class .remark-code-line-highlighted
(function(d) {
  const hlines = d.querySelectorAll('.remark-code-line-highlighted');
  const preParents = [];
  const findPreParent = function(line, p = 0) {
    if (p > 1) return null; // traverse up no further than grandparent
    const el = line.parentElement;
    return el.tagName === "PRE" ? el : findPreParent(el, ++p);
  };

  for (let line of hlines) {
    let pre = findPreParent(line);
    if (pre && !preParents.includes(pre)) preParents.push(pre);
  }
  preParents.forEach(p => p.classList.add("remark-code-has-line-highlighted"));
})(document);</script>
<style>
.logo {
  background-image: url(AU.png);
  background-size: contain;
  background-repeat: no-repeat;
  position: absolute;
  top: 1em;
  right: 1em;
  width: 110px;
  height: 128px;
  z-index: 0;
}
</style>

<script>
document
  .querySelectorAll(
    '.remark-slide-content' +
    // add additional classes to exclude here, e.g.
    // ':not(.inverse)' +
    ':not(.hide-logo)'
  )
  .forEach(el => {
    el.innerHTML += '<div class="logo"></div>';
  });
</script>

<script>
slideshow._releaseMath = function(el) {
  var i, text, code, codes = el.getElementsByTagName('code');
  for (i = 0; i < codes.length;) {
    code = codes[i];
    if (code.parentNode.tagName !== 'PRE' && code.childElementCount === 0) {
      text = code.textContent;
      if (/^\\\((.|\s)+\\\)$/.test(text) || /^\\\[(.|\s)+\\\]$/.test(text) ||
          /^\$\$(.|\s)+\$\$$/.test(text) ||
          /^\\begin\{([^}]+)\}(.|\s)+\\end\{[^}]+\}$/.test(text)) {
        code.outerHTML = code.innerHTML;  // remove <code></code>
        continue;
      }
    }
    i++;
  }
};
slideshow._releaseMath(document);
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
